STLM
Systematically Testing the Evidence on Marijuana

Systematically Testing the Evidence on Marijuana

Cannabis for the Management of Symptoms of PTSD

A Living Systematic Review: Update 2

September 2026

OHSU

Learn More at www.cannabisevidence.org

Table of Contents

Executive Summary 1
- Background 1
- Key Questions and Selection Criteria 1
- Methods 1
- Key Findings 1
- Conclusions 2

Background 3
Key Questions 3
Methods 3
Findings 4
- Priority Outcomes 4
- Other Outcomes 12
- Differences by Subgroups 12
- Ongoing Studies 12

Discussion 13
- Limitations 13
- Applicability to Veteran populations 13
- Conclusions 13

References 14
Appendix A. Methods 17
- Literature Search Strategies 17
- Study Selection 21
- Data Abstraction 23
- Assessment of Risk of Bias of Individual Studies 23
- Data Synthesis 23
- Assessment of the Overall Quality of Evidence 23
- Surveillance in the Living Stage of the Systematic Review 23

Appendix B. Full Evidence Tables 25
Appendix C. Bibliography of Included Studies 38

Suggested citation: Blazina I, Ayers C, Ivlev I, Kansagara D. *Cannabis for the management of symptoms of PTSD: A living systematic review – Update 2*. The Systematically Testing the Evidence on Marijuana Project; 2026. https://www.cannabisevidence.org/evidence-syntheses/ptsd/

Conflict of Interest Disclosures: No authors have conflicts of interest to disclose. All authors have completed and submitted the Oregon Health & Science University form for Disclosure of Potential Conflicts of Interest, and none were reported.

Cover art by Michael Beier on Unsplash

Executive Summary

Background

With the expansion of legal access to cannabis for medical and recreational purposes in the US over the past decades, cannabis use has also increased. Cannabis has been touted for its purported benefits for a wide range of medical purposes, including posttraumatic stress disorder (PTSD). This review seeks to identify and incorporate new evidence through March 2026 to address the benefits and harms of cannabis use (both plant-based and synthesized) for PTSD.

Key Questions and Selection Criteria

KQ1. What are the effects of cannabis on health outcomes and health care utilization for adults who have PTSD?
KQ2. Do the effects differ by subgroup, such as medical and mental health comorbidities?

We included studies (controlled clinical trials and observational studies with comparison groups) that assessed the effects of plant-based cannabis preparations, whole-plant extracts (e.g., nabiximols), or US Food and Drug Administration (FDA)-approved synthesized, pharmaceutically prepared cannabinoids (e.g., dronabinol, nabilone) in nonpregnant adults with PTSD.

Methods

We searched multiple databases and grey literature sources through March 2026 to identify studies of cannabis use in participants with PTSD. Two reviewers independently screened all citations for inclusion, and disagreements were resolved by consensus or a third reviewer. Data from included studies were abstracted by 1 reviewer and confirmed by a second. Two reviewers independently assessed the risk of bias (RoB) of each study and the overall certainty of evidence (CoE) for each outcome using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Disagreements were resolved through discussion. We summarized the primary literature through qualitative synthesis.

Key Findings

We identified 1 new study since our last update, for a total of 8 eligible studies. The new study was a small (N = 29), high-RoB randomized controlled trial (RCT).[1] Of the previously identified studies, 2 were crossover RCTs (1 low- and 1 high-RoB),[2,3] and 5 were retrospective cohort studies.[4-8] We rated 2 of the included cohort studies as having moderate RoB and 3 as having high RoB. One RCT was conducted in Canada, while the other RCTs and the cohort studies were conducted in the US in largely Veterans Affairs (VA) populations. We also identified 10 ongoing studies (all RCTs).

Effectiveness and Harms

- **PTSD symptom severity:** One low-RoB crossover RCT (N = 80), 1 high-RoB RCT (N = 29), and 5 cohort studies (N range = 136 to 2,276) found no difference in PTSD symptom reduction with cannabis (low CoE).
- **PTSD-rel**ated nightmares: One very small (N = 10), high-RoB crossover RCT found significant improvement in PTSD-related nightmares with nabilone (a synthetic cannabinoid) compared to placebo (mean Clinician Administered PTSD Scale [CAPS] recurring and distressing dreams item score change -3.6 [SD = 2.4] versus -1.0 [SD = 2.1], P = .03; very low CoE).
- **Sleep quality:** Two RCTs (N = 10 and 80) and 1 high-RoB cohort study (N = 150) found no difference in any other sleep quality measures with cannabis (very low CoE).
- **Functional status:** The same 3 studies found no difference in global or psychosocial functioning (very low CoE).
- **Mental health:** One low-RoB RCT (N = 80) found smoked cannabis no different than placebo for reduction in general depression or social anxiety (Inventory of Depression and Anxiety Symptoms [IDAS], P = .18 and P = .58 respectively). A high-RoB RCT (N = 29) found no difference between oral CBD and placebo on anxiety (Beck Anxiety Inventory; mean difference -2.20; 95% CI, -7.58 to 3.18) or depression (Beck Depression Inventory; mean difference -2.67; 95% CI, -7.62 to 2.28; very low CoE).
- No studies were identified that analyzed quality of life or utilization of health services.

Differences by Subgroups

- None of the included studies evaluated subgroups.

Applicability to Veteran populations

Most of the research in this field has been conducted in Veterans or active-duty military personnel, making it very applicable to this population.

Conclusions

Although we identified an additional study in this update, it remains uncertain whether cannabis improves symptoms of PTSD. There was low CoE that cannabis use is not associated with differences in PTSD symptoms, and very low CoE that it may improve PTSD-related nightmares but does not affect other measures of sleep quality, functional status, or mental health. Diagnoses of PTSD, particularly in the Veteran population, are increasing—emphasizing the need for future research to evaluate the benefits and harms of cannabis. Fortunately, there are several ongoing studies assessing effects of cannabis on various aspects of PTSD that should be completed over the next several years.

Background

The expansion of legal access to cannabis for medical and non-medical purposes in the US over the past decades has led to increased cannabis use.[9] The percentage of Americans aged 18 and older who report past-month cannabis use has been rising, from 10.5% in 2002 to 18.0% in 2019.[10]

As of September 2025, 40 states and the District of Columbia (DC) have legalized the medical use of cannabis for adults, and 24 states and DC have legalized non-medical adult use.[11] Cannabis is touted for its purported benefits for a wide range of medical purposes, including posttraumatic stress disorder (PTSD). A majority of states with medical cannabis laws list PTSD as an indication for cannabis use.[12] In states where medical cannabis use is legal, PTSD was listed as the primary reason for requesting cannabis by more than one-third of individuals seeking it.[13,14] Yet the evidence regarding effectiveness and harms of cannabis use to treat PTSD is minimal to date.

A 2017 systematic review assessed the benefits and harms of cannabis use in patients with PTSD, with insufficient results.[15] This review was formulated as a living systematic review to incorporate new evidence to address the benefits and harms of cannabis use for PTSD, with an initial report completed in March 2021,[16] and an update in November 2021.[17] As part of our living systematic review protocol, we monitor the literature for new meaningful studies on cannabis for PTSD (Table 1). Since 2021, we had identified no new studies that met our inclusion criteria until now. Given the slow rate of publication of new comparative studies on this topic, we decided to update the full systematic review to include all our surveillance to date, in order to present the most current findings in a single consolidated document.

Table 1. Topic History and Search Dates

Document Type	Search Dates	Date Presented	Number of new studies (total overall studies)
Systematic Review Update #2	March 2026	September 2026	1 (8)
Surveillance 4	April 2025	June 2025	0 (7)
Surveillance 3	January 2024	February 2024	0 (7)
Surveillance 2	December 2022	December 2022	0 (7)
Surveillance 1	April 2022	April 2022	0 (7)
Systematic Review Update #1	October 2021	November 2021	2 (7)
Original Systematic Review	Inception to October 2020	March 2021	5

Key Questions

This systematic review is an update of a 2017 review,[15] and as such, the research questions for this systematic review are the same as the original review. The questions were developed after a topic refinement process that included a preliminary review of published peer-reviewed literature, and consultation with internal partners, investigators, and stakeholders. The research questions are as follows: 1) What are the effects of cannabis on health outcomes and health care utilization for adults who have PTSD? 2) Do the effects differ by patient subgroup, such as patient medical and mental health comorbidities?

Methods

We searched multiple databases and grey literature sources from 2015 to March 31, 2026, to identify studies of cannabis use in participants with PTSD published since the previous review's search dates. To update findings as new evidence emerges, we maintain this as a living systematic review using several approaches: 1) systematically identifying ongoing studies, and searching for the relevant publications, 2) periodically contacting experts to ask about new evidence, and 3) conducting surveillance searches of the literature. Full methods can be found in Appendix A.

We included studies (controlled clinical trials and observational studies using control groups) that assessed the effects of plant-based or FDA-approved synthesized cannabis preparations on PTSD symptoms in nonpregnant adults with PTSD. Two reviewers independently screened all citations for inclusion, and disagreements were resolved by consensus or a third reviewer.

Data on study design, objectives, setting, population characteristics, subject inclusion and exclusion criteria, number of participants, duration of follow-up, the study and comparator interventions, important co-interventions, health outcomes, and harms from included studies were abstracted by 1 reviewer and confirmed by a second.

Two reviewers independently assessed the RoB of each study and disagreements were resolved through discussion. We summarized the primary literature by abstracting relevant data and qualitatively synthesizing the literature. Two independent raters assigned select outcomes a summary judgment for the overall certainty of evidence (CoE) using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach,[18] with disagreements resolved by a third rater. We combined randomized and nonrandomized studies for our GRADE ratings and assessed 6 outcomes:

- Validated PTSD clinical interviews and symptom inventories (e.g., CAPS, PCL, PSS)
- Validated measures of mental health symptoms commonly associated with PTSD (e.g., mood, depression, anxiety)
- Validated measures of sleep quality
- Validated measures of quality of life
- Utilization of health services
- Social functioning/disability/employment

Findings

For this living systematic review update, we reviewed a total of 1,143 citations published since October 2021, the search date for the last version of this review. Of these, 41 qualified for full-text review. We included 1 new RCT[1] evaluating the effects of cannabis use on symptoms of PTSD in addition to the 7 studies included in the previous version of the review: 2 crossover randomized controlled trials (RCTs)[2,3] and 5 cohort studies.[4-8] See Figure 1 for literature flow.

Of the included studies, sample sizes ranged from 10 to 80 participants for randomized studies, and 136 to 2,276 participants in nonrandomized studies. Trial durations were between 7 weeks and 4 months, with observational studies from 30 days to 12 months. One RCT was conducted in Canada, while the other RCTs and the cohort studies were conducted in the US in largely VA populations. Table 2 provides study characteristics. We rated 1 of the RCTs as having low RoB and the other 2 RCTs as high RoB. We rated 2 of the included cohort studies as having moderate RoB and 3 as having high RoB (Appendix Tables B2-B3). The results are organized by outcome of interest. Detailed results by study can be found in Appendix B.

Priority Outcomes

PTSD Symptoms

There was low CoE of no differences in PTSD symptom severity between people who used cannabis and those who did not from 2 RCTs and 5 cohort studies (Table 3). The low-RoB crossover RCT by Bonn-Miller et al. compared 3 different smoked cannabis preparations (i.e., high THC, high CBD, and equivalent THC to CBD ratio) to placebo in Veterans. The authors found no difference in PTSD symptom reduction on either the CAPS-5 or the PCL-5 between any cannabis preparation group and placebo during a 3-week period (CAPS-5, $P = .15$; PCL-5, $P = .11$; Appendix Table B1).[3] This trial also included a crossover phase after a 2-week washout, wherein participants were re-randomized to 1 of the 3 cannabis preparations for another 3 weeks without a placebo group. During this phase, the balanced THC to CBD ratio group experienced the greatest reduction in PTSD symptoms on both scales. We rated the RoB for this study as low (Appendix Table B2). Only the first phase with a placebo comparator was considered for the CoE.

A second small (n=29) high-RoB RCT by Bogenschutz et al. compared 600 mg CBD to placebo over a 7-week period and found no difference in PTSD symptoms between groups (PCL-5 estimated mean difference 1.56; 95% CI, -7.66 to 10.78; $d = 0.13$).[1] Five retrospective cohort studies analyzing PTSD symptoms by cannabis use exposure (rather than treatment with cannabis) also contributed to the evidence. Two studies examined different subsets of participants from a large study of Veterans enrolled in intensive PTSD treatment programs in the VA between 1992 and 2011.[4,5] Another also examined Veterans in a VA single-site, intensive PTSD treatment program between 2008 and 2016.[8] A fourth was a study of Colorado residents with PTSD,[7] and finally, there was a secondary analysis of 2 RCTs (Table 2).[6]

Figure 1. PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases only



**New studies since the search for the first update of the report in October 2021*

Table 2. Characteristics of Included Studies

Author, Year N Year(s) of Study Follow-up	Setting Design Funding	Cannabinoid(s) tested	Sample Description	Demographic Characteristics *total pop.* or *EG vs CG*	Risk of Bias
Randomized Studies					
Bogenschutz et al., 2025[1] N = 29 2019-2022 7 weeks	US: RCT NIAAA (NIH) and Tilray Canada	CBD	Adults with moderate to severe AUD with PTSD or subthreshold PTSD	38% male Age, mean (SD): 38.6 (10.4) 45% White, 41% Black, 14% Other; 41% Hispanic Mean PCL: 45.7 (13.4)	High
Bonn-Miller et al., 2021[3] N = 80 Year NR 10 weeks	US: Crossover RCT CDPHE and MAPS	THC and/or CBD	Military Veterans with PTSD	90% male Age, mean (SD): 44.9 (13.8) 66% White Employed (full- or part-time): 29% Some college: 52.5% College graduate: 40%	Low
Jetly et al., 2015[2] N = 10 Year NR 4 months	Canada: Crossover RCT Funding NR	Synthetic THC (Nabilone)	Active-duty military with PTSD	100% male Age, mean (SD): 43.6 (8.2) 100% White	High

Author, Year N Year(s) of Study Follow-up	Setting Design Funding	Cannabinoid(s) tested	Sample Description	Demographic Characteristics *total pop.* or *EG vs CG*	Risk of Bias
Nonrandomized Studies					
Bonn-Miller, 2020[7] N = 150 12 months	US: prospective cohort CDPHE	Not specified	Colorado residents with PTSD	69% vs 77% male Age, mean (SD): 44.36 (12.64) vs 57.49 (15.32) 69% White; 15% AA/ Black; 5% AI/AN; 2% Multiracial; 9% Other	High
De Aquino et al., 2020[4] N = 1,413 1992-2011 4 months	US: VA retrospective cohort VHA	Not specified	Veterans receiving intensive PTSD treatment, and with non-medical opioid use	74.7% vs 67.0% male Age, mean (SD): 45.8 (10.1) vs 48.4 (9.2) 55.4% White; 27.7% AA/ Black; 5.8% Latino Unemployed: 91.0% vs 88.8%	Moderate
Petersen et al., 2021[8] N = 340 2008-2016 12 sessions, min. 30 days	US: VA retrospective cohort NR	Not specified	Random sample of Veterans aged 18 to 85 years with PTSD enrolled in intensive PTSD treatment	96.3% vs. 94.6% male; *P* = .77 Age, years (SD): 37.7 (15.1) vs. 39.2 (14.6); *P* = .15 White: 82.7% vs. 88.4% AA/Black: 16.0% vs. 7.3% Other: 1.2% vs. 4.2% *P* = .03 Comorbid SUD: 43.2% vs. 11.2%, P < .001	High
Ruglass et al., 2017[6] N = 136 2006-2014 12 months[19]; 3 months[20]	US: retrospective cohort NIDA and NIAAA	Not specified	Participants with co-occurring PTSD and SUDs who received CBT and Sertraline or placebo in 1 of 2 primary RCTs	47.8% male Age, mean (SD): 41.6 (9.38) vs 44 (9.18) 18.4% White; 55.1% AA/ Black; 15.4% Latino Education: 13.08 (1.88) vs 13.28 (2.52) years	High

Author, Year N Year(s) of Study Follow-up	Setting Design Funding	Cannabinoid(s) tested	Sample Description	Demographic Characteristics *total pop.* or *EG vs CG*	Risk of Bias
Wilkinson et al., 2015[5] N = 2,276 1992-2011 4 months	US: VA retrospective cohort NIMH and VHA	Not specified	Veterans receiving intensive PTSD treatment, excluding those with previous problematic drug or alcohol use	96.7% male Age, mean (SD): 51.7 (8.6) 72.7% White; 21.2% AA/ Black; 6.1% Other Education: 12.9 (1.9) years	Moderate

Highlight indicates new studies in this update.

Abbreviations. AA: African American, AI: American Indian, AN: Alaska Native, AUD: alcohol use disorder, CBD: cannabidiol, CBT: cognitive behavioral therapy, CDPHE: Colorado Department of Public Health and Environment, CG: control group, EG: exposure group, MAPS: The Multidisciplinary Association for Psychedelic Studies, NIAAA: National Institute on Alcohol Abuse and Alcoholism, NIDA: National Institute on Drug Abuse, NIMH: National Institute of Mental Health, NR: not reported, PCL: PTSD Checklist, PTSD: posttraumatic stress disorder, RCT: randomized controlled trial, SUD: substance use disorder, THC: tetrahydrocannabinol, VA: Veterans Affairs, VHA: Veterans Health Administration.

One of the cohort studies, conducted by Wilkinson et al.,[5] carried forward from the 2017 systematic review. The cohort consisted of 2,276 Veterans with PTSD and without problematic alcohol use or recent drug use other than cannabis. They were interviewed before entering PTSD treatment and 4 months after discharge. The cohort was analyzed by 4 groups defined as:

- "Never users" reported no cannabis use before admission or anytime during the study at follow-up
- "Continuing users" who reported cannabis use at both timepoints
- "Stoppers" who reported use at baseline, but no use at follow-up
- "Starters" who reported no baseline use but reported use 4 months after treatment
- The continuing users and starters groups had significantly worse PTSD scores (using the Short-form Mississippi Scale [MISS] for PTSD) at follow-up than never-users and stoppers ($P < .0001$) after adjusting for multiple confounders. However, as noted by O'Neil et al.,[15] the absolute differences in scores were small (mean MISS score 36.64 for stoppers and 39.67 for starters, $P < .01$; Appendix Table B1).

The second cohort study analyzing a different subset of Veterans from the intensive PTSD treatment study at the VA was conducted by De Aquino et al.[4] They examined the subgroup of Veterans with PTSD and nonmedical opioid use (≥ 7 days in the past month; N = 1,413). The cohort was divided into those who had versus had not used cannabis ≥ 7 days in the preceding month. There was no difference between groups in change in PTSD severity from baseline to 4-month follow-up (Appendix Table B1).[4] The RoB for both of these studies was rated as moderate primarily due to group differences in baseline characteristics (Appendix Table B3).

A single VA site, retrospective cohort study (N = 340) of Veterans in intensive PTSD treatment was conducted by Petersen et al.[8] This study compared people who used cannabis identified by 1 or more of several different records (i.e. diagnosis of cannabis abuse or dependence, progress notes mention cannabis use, THC-positive urinary drug screen [UDS], or medical cannabis prescription according to non-VA medication list) with those who had no record of cannabis use. They found no difference in change in PCL-5 scores (5.7 [14.7] versus 6.0 [14.0]; $P = .79$) nor odds of treatment success defined as a 5-point or more improvement on the PCL-5 (aOR, 1.4 [95% CI, 0.81 to 2.5]) between people who used cannabis and nonusers (Appendix Table B1). We rated this study as high RoB because of imbalance in baseline characteristics and psychological treatment, as well as the possibility of misclassification of exposure status (Appendix Table B3).

The Colorado cohort study (N = 150) by Bonn-Miller et al.[7] followed people who used cannabis and nonusers for a year and found PTSD symptoms (as measured by the CAPS-5) improved to a greater extent among people who used cannabis than nonusers over 12 months (CAPS-5 PTSD symptom severity group by time interaction: -0.32 [95% CI, -0.59 to -0.05]; Appendix Table B1). However, the absolute difference in symptom severity scores was small and below suggested thresholds for clinically meaningful change.[21] Moreover, there were several methodologic issues with the study that temper confidence in conclusions, including the presence of important baseline differences in group characteristics, a high attrition rate, and the use of complete-case analysis (i.e. those who stopped using cannabis during the study period were not included in final analyses). Further, as the authors appropriately discuss, people in the cannabis use group had been using before enrollment and yet the baseline symptom severity was similar between groups. It is challenging to know whether differences emerging during the study period were related to a true effect of the intervention, or rather to the effect of being observed.

The final cohort study (N = 136) by Ruglass et al. was a secondary analysis of the results of two 12-week RCTs of cognitive behavioral therapy (CBT), 1 of which also included sertraline or placebo taken concomitantly for co-occurring PTSD and substance use disorders (SUD; Table 1).[6] The study found no correlation between cannabis use days measured by the Substance Use Inventory (SUI) at baseline and PTSD symptom severity measured by the CAPS at follow-up. Additionally, higher weekly cannabis use was associated with greater weekly PTSD symptom severity (as measured by the Modified PTSD Symptom Scale Self-Report [MPSS-SR]) early in treatment, but lower weekly severity later in treatment (Appendix Table B1). The RoB for this study was high due to differences in baseline characteristics, heterogeneity in study populations and interventions, missing data, and not accounting for all important potential confounders (Table 2).

PTSD-related Nightmares

We found very low CoE of improvement in PTSD-related nightmares with nabilone (a synthetic cannabinoid) from 1 RCT (Table 3). This trial by Jetly et al.[2] was very small (N = 10) and used a crossover design to test nabilone versus placebo for PTSD-related nightmares in Canadian men on active military duty. Nabilone titrated up to 3 mg

per day, or matching placebo were administered for 7 weeks, followed by a 2-week washout period and crossover to another 7-week treatment period. The study found a significantly greater reduction in both frequency and intensity of recurring and distressing dreams, as measured by CAPS, with nabilone compared to placebo (mean score change -3.6 [SD = 2.4] versus -1.0 [SD = 2.1], *P* = .03; Appendix Table B1). The study was rated high RoB due to insufficient information on randomization and allocation concealment, lack of reporting baseline differences by group, lack of appropriate statistical methods to account for the crossover design (i.e., conditional analyses) and not reporting results for each period separately.

Other Sleep-related Measures

There was very low CoE of no significant difference in sleep quality measures between people who used cannabis and those who did not from 2 RCTs and 1 cohort study. The Bonn-Miller et al. trial (moderate RoB) found no difference in change in insomnia severity with the Insomnia Severity Index (ISI) for any form of smoked cannabis compared with placebo (*P* = .40).[3] Jetly et al. (high RoB) found no difference in sleep quality or quantity with nabilone treatment versus placebo (CAPS difficulty falling and staying asleep items and sleep diary).[2] The cohort study by Bonn-Miller et al. also found no difference on numerous sleep quality-related measures, with the exception of number of awakenings, for which people who used cannabis experienced greater improvement (Table 3 and Appendix Table B1).[7]

Functional Status

There was very low CoE of no difference in functional status between those using cannabis and nonusers from 2 RCTs and 1 cohort study. The RCT by Bonn-Miller et al. (N = 80) found any strain of smoked cannabis was no different than placebo for change in psychosocial functioning on the Inventory of Psychosocial Functioning (IPF; *P* = .27).[3] The small (N = 10) and high-RoB RCT by Jetly et al. examined improvement in global functioning with nabilone compared with placebo as measured by the Clinical Global Impression of Change and found marginally significant difference (CGI-C; 1.9 ± 1.1 [i.e., much improved] versus 3.2 ± 1.2 [i.e., minimally improved], *P* = .05).[2] The cohort study by Bonn-Miller et al. found no difference in psychosocial functioning (measured by the IPF) between exposed and unexposed groups (group by time interaction: 0 [95% CI, -0.02 to 0.02]; Appendix Table B1).[7]

Mental Health Symptoms

There was very low CoE from 2 RCTs that there was no difference in mental health symptoms with cannabis compared to placebo. The moderate-RoB Bonn-Miller et al. RCT found that any preparation of smoked cannabis was no different than placebo for reduction in general depression (*P* = .18) or social anxiety (*P* = .58) as measured by the Inventory of Depression and Anxiety Symptoms (IDAS; Table 2 and Appendix Table B1).[3] A second RCT by Bogenschutz et al. also reported no differences in depression (as measured by the Beck Depression Inventory; mean difference -2.67; 95% CI, -7.62 to 2.28; *d* = -.42) or anxiety (as measured by the Beck Anxiety Inventory; mean difference -2.20; 95% CI, -7.58 to 3.18; *d* = -.33).[1]

Table 3. Summary of Findings (GRADE)

Outcome Studies; Sample Size	Certainty of Evidence (CoE)	Relationship	Rationale for CoE rating
PTSD symptom severity 2 RCTs[1,3]; N = 109 5 cohort studies[4-8]; N = 4,315	⊕⊕◯◯ Low	No difference: Cannabis was not associated with clinically significant improvement in symptom severity in the trials or cohort studies	Downgraded 1 level each for RoB and indirectness
PTSD-related nightmares 1 RCT[2]; N = 10	⊕◯◯◯ Very low	Nabilone significantly reduced frequency and intensity of recurring and distressing dreams	Downgraded 1 level each for RoB, imprecision, and indirectness
Sleep quality 2 RCTs[2,3]; N = 90 1 cohort study[7]; N = 150	⊕◯◯◯ Very low	No difference: No difference in insomnia, or sleep quality or quantity with cannabinoids compared to placebo in RCTs and no association with any sleep quality measures in the cohort study	Downgraded 1 level each for RoB, imprecision, and indirectness
Functional status 2 RCTs[2,3]; N = 90 1 cohort study[7]; N = 150	⊕◯◯◯ Very low	No difference: No difference in global functioning or psychosocial functioning in RCTs or cohort study	Downgraded 1 level each for RoB, imprecision, and indirectness
Mental health symptoms 2 RCTs[1,3]; N = 109	⊕◯◯◯ Very low	No difference: Smoked or oral cannabis (THC and/or CBD) was no different than placebo for reduction in general depression or social anxiety	Downgraded 1 level each for RoB, imprecision, and indirectness
Quality of life	Not applicable	---	---
Utilization of health services	Not applicable	---	---

Abbreviations. CoE: Certainty of Evidence, GRADE: Grading of Recommendations, Assessment, Development, and Evaluation, PTSD: posttraumatic stress disorder, RCT: randomized controlled trial, RoB: risk of bias.

⊕◯◯◯ Very Low

⊕⊕◯◯ Low

⊕⊕⊕◯ Moderate

⊕⊕⊕⊕ High

Other Outcomes

Other Substance Use

Three cohort studies examined some measures of other substance use by cannabis use groups. Wilkinson et al. administered the Addiction Severity Index (ASI). In general, those who started or continued to use cannabis during the study had higher alcohol and substance abuse scores than those who never used or quit. Specifically, they found cannabis starters had significantly more alcohol misuse than continuing users, never-users, and stoppers, while continuing users had significantly more alcohol misuse than stoppers. Continuing users and starters also had significantly more misuse of other substances than never-users and stoppers ($P < .01$ for paired comparisons).[5] De Aquino et al. also analyzed ASI substance use indices and other substance use measures and found no difference between Veterans with PTSD who were using opioids and cannabis, and those who reported no cannabis use.[4] Finally, Ruglass et al. found baseline days of cannabis use were not a significant predictor of other substance use at the end of treatment ($P = .84$).[6]

Employment

Wilkinson et al. reported results of the ASI employment item at follow-up and found no significant differences in employment status between cannabis use groups ($P = .58$).[5]

Violent Behavior

Wilkinson et al. also examined a measure of violent behavior, a 4-item questionnaire from the National Vietnam Veterans Readjustment Study,[22] and found starters had significantly more violent behavior than continuing users, never-users, and stoppers at follow-up ($P < .0001$).[5]

Other Harms

Only the RCT by Bonn-Miller et al. reported between-group rates of other harms. One or more of the cannabis use groups had > 10% higher rates of dry mouth, back pain, dizziness, somnolence, irritability, and paranoia than the placebo group.[3] For details see Appendix Table B1.

Differences by Subgroups

None of the included studies evaluated subgroups.

Ongoing Studies

We identified 10 ongoing studies of cannabis for PTSD, all were RCTs (Table 4). Estimated sample sizes of the ongoing studies range from 21 to 500 participants. Four studies have been completed but not yet published, while the others are expected to finish within the next 1 to 5 years.

Table 4. Eligible Ongoing/Unpublished Studies of Cannabis for PTSD

ClinicalTrials.gov Identifier	Study Title	Study Design	Estimated Enrollment	Estimated Primary Completion Date Status
NCT05132699	Enhancing Prolonged Exposure with Cannabidiol to Treat Posttraumatic Stress Disorder[23]	RCT	21 (actual)	June 2023 (actual) Completed, results posted October 2024 (not yet published)
NCT04448808	Treating Nightmares in Posttraumatic Stress Disorder with Dronabinol[24]	RCT	170 (actual)	January 2025 (actual) Completed, no results posted
NCT04080427	Effects of Delta 9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study[25]	RCT	102 (actual)	May 2025 Completed, no results posted
NCT03518801	Cannabidiol and Prolonged Exposure (CBD-PE)	RCT	136 (actual)	September 2025 Completed, no results posted
EUCT number: 2024-514783-78-00	BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms	RCT	82	December 2025 Ongoing, recruitment closed

NCT04550377	Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI	RCT	120	June 2026 Recruiting
NCT07224698	Inhaled Cannabis for Treatment of PTSD[26]	RCT	320	November 2027 Not yet recruiting
NCT05269459	Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults	RCT	180	April 2029 Recruiting
NCT06381180	Warrior CARE: Cannabis Behavioral Health	RCT	500	December 2030 Not yet recruiting
NCT06222268	Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery (CAPER)	RCT	280	September 2031 Not yet recruiting

Abbreviations. CBD: cannabidiol, PTSD: posttraumatic stress disorder, RCT: randomized controlled trial, TBI: traumatic brain injury

Discussion

We identified 3 RCTs (2 crossover; 1 low- and 2 high-RoB) and 5 cohort studies (2 moderate- and 3 high-RoB) that provided evidence regarding cannabis use for PTSD. There was low CoE of no difference with cannabis for reduction in severity of PTSD symptoms, and very low CoE for improvement in intensity and frequency of disturbing dreams with nabilone. For all other sleep quality measures, there was very low CoE of no difference between people who used cannabis and those who did not. There was also very low CoE for no evidence of an effect of cannabis on mental health symptoms and no difference in functional status with cannabis use. We did not identify any randomized or nonrandomized studies that evaluated quality of life, or utilization of health services.

Five of the included studies have been published since the 2017 review, and 1 of those, the Bogenschutz et al. RCT,[1] was published since our previous version of the report, which highlights the overall low rate and volume of research being conducted and published on cannabis for PTSD.[4,7]

Limitations

The existing evidence base is significantly limited by study design and quality issues. We rated all but 1 of the included studies as moderate- or high-RoB. Cannabis use was self-reported or deduced from electronic health records in all observational studies with no measures of dose, compounds, or modes of administration. Additionally, the applicability of existing studies is limited by inclusion of dual-substance use, heavily male study populations, and inclusion of only Veterans also receiving intensive PTSD treatment and active military personnel. Only 3 studies included nonmilitary or nonveteran participants; one was restricted to residents of Colorado state, while the others were in adults with both PTSD and other SUDs, in one case receiving concomitant therapy. These factors limit the applicability to the larger US population that suffers from PTSD.

Applicability to Veteran populations

Most of the research in this field has been conducted in Veterans or active-duty military personnel. As such, the evidence base is highly applicable to these groups. However, overall, it is still unclear whether cannabis is an efficacious and safe intervention to manage PTSD symptoms in Veterans.

Conclusions

There was low certainty evidence cannabis use is not associated with differences in PTSD symptoms, and very low CoE it may improve PTSD-related nightmares but does not affect other measures of sleep quality, functional status, or mental health symptoms. There continues to be a dearth of literature on the effects of cannabis use on PTSD. As cannabis continues to be decriminalized and legalized by states across the country, access will increase. Large, controlled trials are needed to establish evidence on the efficacy and harms of cannabis for PTSD, and studies should specify the cannabinoid compounds (e.g., THC, CBD) being evaluated. Several such studies are ongoing and expected to be completed in the next few years.

References

1. Bogenschutz MP, Blessing E, Dgheim D, et al. Effects of cannabidiol in alcohol use disorder patients with and without co-occurring post-traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof-of-concept trials. *Alcohol Clin Exp Res (Hoboken).* 2026;50(1):e70212. doi: 10.1111/acer.70212.

2. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology.* 2015;51:585–588. doi: 10.1016/j.psyneuen.2014.11.002.

3. Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. *PLoS ONE.* 2021;16(3):e0246990. doi: 10.1371/journal.pone.0246990.

4. De Aquino JP, Sofuoglu M, Stefanovics EA, Rosenheck RA. Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. *Am J Drug Alcohol Abuse.* 2020;46(6):812–822. doi: 10.1080/00952990.2020.1818248.

5. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. *J Clin Psychiatry.* 2015;76(9):1174–1180. doi: 10.4088/JCP.14m09475.

6. Ruglass LM, Shevorykin A, Radoncic V, et al. Impact of Cannabis Use on Treatment Outcomes among Adults Receiving Cognitive-Behavioral Treatment for PTSD and Substance Use Disorders. *J.* 2017;6(2):07. doi: 10.3390/jcm6020014.

7. Bonn-Miller MO, Brunstetter M, Simonian A, et al. The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder. *Cannabis Cannabinoid Res.* 2022;7(2):214–223. doi: 10.1089/can.2020.0056.

8. Petersen M, Koller K, Straley C, Reed E. Effect of cannabis use on PTSD treatment outcomes in veterans. *Ment Health Clin.* 2021;11(4):238–242. doi: 10.9740/mhc.2021.07.238.

9. Substance Abuse and Mental Health Services Administration. *Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53).* Rockville, MD2018.

10. Ayers C, Robalino S, Shaw B, Ward R, Kansagara D. Prevalence and risk of developing cannabis use disorder in adults who use cannabis, living systematic review: update 1. The Systematically Testing the Evidence on Marijuana (STEM) Project. 2025; https://www.cannabisevidence.org/evidence-syntheses/adult-cannabis-use-disorder/. Accessed May 14, 2025.

11. Systematically Testing the Evidence on Marijuana (STEM) Project. Policy Map. https://www.cannabisevidence.org/policy/. Accessed August 7, 2026.

12. ProCon.org. Legal medical marijuana states and DC: laws, fees, and possession limits. https://medicalmarijuana.procon.org/legal-medical-marijuana-states-and-dc/. Accessed March 18, 2021.

13. Bowles DW. Persons registered for medical marijuana in the United States. *J Palliat Med.* 2012;15(1):9–11. doi: 10.1089/jpm.2011.0356.

14. Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. *Am J Addict.* 2013;22(3):277–284. doi: 10.1111/j.1521-0391.2012.12018.x.

15. O'Neil ME, Nugent SM, Morasco BJ, et al. Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder: A Systematic Review. *Ann Intern Med.* 2017;167(5):332–340. doi: 10.7326/m17-0477.

16. Ayers C, Harrod C, Durbin S, et al. Cannabis for the management of symptoms of PTSD: a living systematic review. The Systematically Testing the Evidence on Marijuana (STEM) Project. 2021; https://www.cannabisevidence.org/evidence-syntheses/ptsd/. Accessed August 11, 2025.

17. Ayers C, Harrod C, Durbin S, et al. Cannabis for the management of symptoms of PTSD - Update 1: A living systematic review. The Systematically Testing the Evidence on Marijuana (STEM) Project; 2021; https://www.cannabisevidence.org/wp-content/uploads/2021/12/PTSDreviewUpdateDecember2021.pdf. Accessed August 7, 2026.

18. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook. Accessed October 30, 2020.

19. Hien DA, Levin FR, Ruglass LM, et al. Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial. *J Consult Clin Psychol.* 2015;83(2):359–369. doi: 10.1037/a0038719.

20. Ruglass LM, Lopez-Castro T, Papini S, Killeen T, Back SE, Hien DA. Concurrent Treatment with Prolonged Exposure for Co-Occurring Full or Subthreshold Posttraumatic Stress Disorder and Substance Use Disorders: A Randomized Clinical Trial. *Psychother Psychosom.* 2017;86(3):150–161. doi: 10.1159/000462977.

21. Stefanovics EA, Rosenheck RA, Jones KM, Huang G, Krystal JH. Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder. *Psychiatr Q.* 2018;89(1):141–155. doi: 10.1007/s11126-017-9522-y.

22. Kulka RA, Schlenger WE, Fairbank JA, et al. *Trauma and the Vietnam war generation: report of findings from the National Vietnam Veterans Readjustment Study.* Philadelphia, PA, US: Brunner/Mazel;1990. 0-87630-573-7 (Hardcover).

23. Straud CL, Roache JD, Ginsburg BC, et al. Enhancing massed prolonged exposure with cannabidiol to improve posttraumatic stress disorder: Design and methodology of a pilot randomized clinical trial. *Contemp Clin Trials Commun.* 2024;38(101270):101270. doi: 10.1016/j.conctc.2024.101270.

24. Roepke S, Schoofs N, Priebe K, et al. Treating nightmares in posttraumatic stress disorder with dronabinol: study protocol of a multicenter randomized controlled study (THC PTSD-trial). *BMC Psychiatry.* 2023;23(1):319. doi: 10.1186/s12888-023-04818-5.

25. Rabinak CA, Kilgore PE, Lumley MA, Rauch SAM. Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol. *Contemp Clin Trials.* 2026;160:108148. doi: 10.1016/j.cct.2025.108148.

26. Multidisciplinary Association for Psychedelic Studies. Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). https://maps.org/marijuana/mjp2/.

27. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol.* 2016;75:40–46. doi: 10.1016/j.jclinepi.2016.01.021.

28. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *Jama.* 2015;313(24):2456–2473. doi: 10.1001/jama.2015.6358.

29. Scottish Intercollegiate Guidelines Network. Methodology checklist 2: randomised controlled trials. 2015; https://www.sign.ac.uk/what-we-do/methodology/checklists/. Accessed October 30, 2020.

30. Scottish Intercollegiate Guidelines Network. Methodology checklist 3: cohort studies. 2014; https://www.sign.ac.uk/what-we-do/methodology/checklists/. Accessed October 30, 2020.

31. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD.

32. Rosenheck RA, Fontana A. Post-september 11 admission symptoms and treatment response among veterans with posttraumatic stress disorder. *Psychiatr Serv.* 2003;54(12):1610–1617. doi: 10.1176/appi.ps.54.12.1610.

Appendix A. Methods

Literature Search Strategies

We conducted a primary review of the literature by systematically searching, reviewing, and analyzing the scientific evidence as it pertained to the key questions. Search strategies were developed in consultation with a research librarian, and peer reviewed by a second research librarian using Peer Review of Electronic Search Strategies (PRESS) guidelines.[27] This updated search strategy was expanded to include updated MeSH and keyword terms, new FDA-approved formulations, and trialed medical marijuana dispensary products not searched in the 2017 review. Only English-language publications were included. For the 2021 report, we searched Ovid MEDLINE ALL, Embase.com, Ovid PsycINFO, PTSDpubs, Ovid EBM Reviews (Cochrane Central, CDSR), and grey literature sources. We further consulted experts and reviewed the bibliographies of relevant articles to identify additional studies.

For this living systematic review, updated searches will be run annually. Prior to conducting updated searches, we will review the efficiency of the search strategy and make refinements as appropriate. This surveillance search strategy is a narrow version of the full search strategy used for the original systematic review. Initially, we proposed the team focus on searching a large electronic database, such as MEDLINE or PubMed, plus clinical trial registries (e.g., ClinicalTrials.gov, WHO, ISRCTN). Clinical trial registries will be important for identification of eligible registered studies. However, additional searching through Google Scholar and electronic databases may be required to identify publications. Besides databases and trial registries, we will manually search the reference lists of all newly included studies and any new and relevant systematic reviews. We will ask the Systematically Testing the Evidence of Marijuana (STEM) Technical Expert Panel (TEP) to highlight any new relevant studies not identified by database searches and to identify any new areas of clinical concern around PTSD.

Search methods and strategies will be reviewed annually, to ensure they reflect any terminology changes in the topic area, or in the databases.

To date, we ceased searching databases that were lower yielding and had provided few citations not identified by other databases. After April 2022 we discontinued use of EMBASE. After the February 2024 search we discontinued use of PTSDpubs. The cannabis search terms were also revised in the 2024 search.

Ovid MEDLINE ALL 1946 to March 30, 2026

1. Stress Disorders, Post-traumatic/ or Stress Disorders, Traumatic/ or Stress Disorders, Traumatic, Acute/ or Anxiety Disorders/ or "Trauma and Stressor Related Disorders"/

2. (PTSD or ((posttraumatic or post-traumatic) adj2 (stress or neurosis or neuroses or disorder*)) or ((anxiety or stress or stressor or trauma*) adj2 disorder*)).ti,ab,kw,kf.

3. or/1-2

4. *Cannabinoids/ or *Cannabinol/ or *Cannabidiol/ or *Medical Marijuana/ or *Marijuana Abuse/ or *Marijuana Smoking/ or *"Marijuana Use"/ or *Endocannabinoids/ or *Dronabinol/ or *Cannabis/

5. (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).ab. /freq=2 or (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).ti,kf,nm.

6. (CBD or CBDA or CBDV or GWP42006 or GWP-42006).ab. /freq=2 or (CBD or CBDA or CBDV or GWP42006 or GWP-42006).ti,kf,nm.

7. (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).ab. /freq=2 or (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).ti,kf,nm.

8. (Cesamet* or Canemes* or Cesametic or Nabilone or "Lilly 109514" or Lilly109514 or "LY 109514" or LY109514 or cpd109514 or cpd-109514).af.

9. (Dexanabinol* or Hu-210 or hu210 or Hu-211 or hu211 or ETS2101).af.

10. (Dronabinol* or Marinol* or Syndros* or Reduvo* or Adversa or Ronabin or dronabinolum or deltanyne or ea-1477 or ea1477 or tetranabinex or qcd-84924 or qcd84924).af.

11. (Epidiolex* or Epidyolex*).af.

12. Levonantradol.af.

13. (Nabiximols* or Nabidiolex* or Sativex* or NanaBis or Tetrabinex or “GW-1000” or gw1000 or SAB-378 or sab378).af.

14. (Bedica* or Bediol* or Bedrobinol* or Bedrocan* or Bedrolite*).af.

15. or/4-14

16. 3 and 15

17. (exp Animals/ not Humans/) or (“animal model” or “animal models” or animals or bovine or canine or cat or cats or cow or cows or dog or dogs or feline or hamster or hamsters or mice or monkey or monkeys or mouse or murine or ovine or pig or pigs or porcine or rabbit or rabbits or rat or rats or rodent* or sheep or veterinary).ti.

18. 16 not 17

19. limit 18 to yr=”2025 -Current”

20. limit 19 to english language

21. (“2025 jan *” or “2025 feb *” or “2025 mar *” or 202501* or 202502* or 202503* or “2025 01 *” or “2025 02 *” or “2025 03 *”).dp.

22. 20 not 21

EBM Reviews - Cochrane Central Register of Controlled Trials March 30, 2026

1. Stress Disorders, Post-traumatic/ or Stress Disorders, Traumatic/ or Stress Disorders, Traumatic, Acute/ or Anxiety Disorders/ or “Trauma and Stressor Related Disorders”/

2. (PTSD or ((posttraumatic or post-traumatic) adj2 (stress or neurosis or neuroses or disorder*)) or ((anxiety or stress or stressor or trauma*) adj2 disorder*)).ti,ab,kw,kf.

3. or/1-2

4. *Cannabinoids/ or *Cannabinol/ or *Cannabidiol/ or *Medical Marijuana/ or *Marijuana Abuse/ or *Marijuana Smoking/ or *”Marijuana Use”/ or *Endocannabinoids/ or *Dronabinol/ or *Cannabis/

5. (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).ab. /freq=2 or (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).ti,kf.

6. (CBD or CBDA or CBDV or GWP42006 or GWP-42006).ab. /freq=2 or (CBD or CBDA or CBDV or GWP42006 or GWP-42006).ti,kf.

7. (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).ab. /freq=2 or (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).ti,kf.

8. (Cesamet* or Canemes* or Cesametic or Nabilone or “Lilly 109514” or Lilly109514 or “LY 109514” or LY109514 or cpd109514 or cpd-109514).af.

9. (Dexanabinol* or Hu-210 or hu210 or Hu-211 or hu211 or ETS2101).af.

10. (Dronabinol* or Marinol* or Syndros* or Reduvo* or Adversa or Ronabin or dronabinolum or deltanyne or ea-1477 or ea1477 or tetranabinex or qcd-84924 or qcd84924).af.

11. (Epidiolex* or Epidyolex*).af.

12. Levonantradol.af.

13. (Nabiximols* or Nabidiolex* or Sativex* or NanaBis or Tetrabinex or “GW-1000” or gw1000 or SAB-378 or sab378).af.

14. (Bedica* or Bediol* or Bedrobinol* or Bedrocan* or Bedrolite*).af.

15. or/4-14

16. 3 and 15

17. (exp Animals/ not Humans/) or (“animal model” or “animal models” or animals or bovine or canine or cat or cats or cow or cows or dog or dogs or feline or hamster or hamsters or mice or monkey or monkeys or mouse or murine or ovine or pig or pigs or porcine or rabbit or rabbits or rat or rats or rodent* or sheep or veterinary).ti.

18. 16 not 17

19. limit 18 to yr=”2025-Current”

EBM Reviews - Cochrane Database of Systematic Reviews 2005 to March 30, 2026

1. (PTSD or ((posttraumatic or post-traumatic) adj2 (stress or neurosis or neuroses or disorder*)) or ((anxiety or stress or stressor or trauma*) adj2 disorder*)).ti,ab,kw.

2. (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).ab. /freq=2 or (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).ti.

3. (CBD or CBDA or CBDV or GWP42006 or GWP-42006).ab. /freq=2 or (CBD or CBDA or CBDV or GWP42006 or GWP-42006).ti.

4. (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).ab. /freq=2 or (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).ti.

5. (Cesamet* or Canemes* or Cesametic or Nabilone or “Lilly 109514” or Lilly109514 or “LY 109514” or LY109514 or cpd109514 or cpd-109514).af.

6. (Dexanabinol* or Hu-210 or hu210 or Hu-211 or hu211 or ETS2101).af.

7. (Dronabinol* or Marinol* or Syndros* or Reduvo* or Adversa or Ronabin or dronabinolum or deltanyne or ea-1477 or ea1477 or tetranabinex or qcd-84924 or qcd84924).af.

8. (Epidiolex* or Epidyolex*).af.

9. Levonantradol.af.

10. (Nabiximols* or Nabidiolex* or Sativex* or NanaBis or Tetrabinex or “GW-1000” or gw1000 or SAB-378 or sab378).af.

11. (Bedica* or Bediol* or Bedrobinol* or Bedrocan* or Bedrolite*).af.

12. or/2-11

13. 1 and 12

14. (“animal model” or “animal models” or animals or bovine or canine or cat or cats or cow or cows or dog or dogs or feline or hamster or hamsters or mice or monkey or monkeys or mouse or murine or ovine or pig or pigs or porcine or rabbit or rabbits or rat or rats or rodent* or sheep or veterinary).ti.

15. 13 not 14

16. limit 15 to yr=”2025-Current”

Ovid PsycINFO 1806 to March Week 4 2026

1. posttraumatic stress disorder/ or complex ptsd/ or desnos/ or acute stress disorder/ or post-traumatic stress/ or anxiety disorders/ or "stress and trauma related disorders"/

2. (PTSD or ((posttraumatic or post-traumatic) adj2 (stress or neurosis or neuroses or disorder*)) or ((anxiety or stress or stressor or trauma*) adj2 disorder*)).tw.

3. or/1-2

4. *Cannabis/ or *Cannabidiol/ or *Cannabinoids/ or *Cannabinol/ or *Dronabinol/ or *Endocannabinoids/ or *Medical Marijuana/ or *Marijuana Smoking/ or *Marijuana Abuse/ or *"Marijuana Use"/

5. *hashish/ or *marijuana/ or *marijuana usage/ or *tetrahydrocannabinol/ or *"Hemp (Cannabis)"/

6. (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).ab. /freq=2 or (cannabi* or mari?uana or hashish or hash or ganja? or hemp or bhang or charas or endocannabinoid* or endo-cannabinoid* or phytocannabi* or phyto-cannabi*).tw.

7. (CBD or CBDA or CBDV or GWP42006 or GWP-42006).ab. /freq=2 or (CBD or CBDA or CBDV or GWP42006 or GWP-42006).tw.

8. (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).ab. /freq=2 or (THC* or tetrahydr?cannabi* or tetra-hydr?cannabi*).tw.

9. (Cesamet* or Canemes* or Cesametic or Nabilone or "Lilly 109514" or Lilly109514 or "LY 109514" or LY109514 or cpd109514 or cpd-109514 or 51022-71-0 or 2N4O9L084N).af.

10. (Dexanabinol* or Hu-210 or hu210 or Hu-211 or hu211 or ETS2101 or 112924-45-5 or R6VT8U5372).af.

11. (Dronabinol* or Marinol* or Syndros* or Reduvo* or Adversa or Ronabin or dronabinolum or deltanyne or ea-1477 or ea1477 or tetranabinex or qcd-84924 or qcd84924 or 7663-50-5 or 7J8897W37S).af.

12. (Epidiolex* or Epidyolex*).af.

13. (Levonantradol or nantradol or D-nantradol or L-nantradol or Nantrodolum or 9KB5WI7MQ6).af.

14. (Nabiximol* or Nabidiolex* or Sativex* or NanaBis or Tetrabinex or "GW-1000" or gw1000 or SAB-378 or sab378 sab378 or 13956-29-1 or 56575-23-6 or K4H93P747O).af.

15. (Bedica* or Bediol* or Bedrobinol* or Bedrocan* or Bedrolite*).af.

16. or/4-15

17. 3 and 16

18. ("animal model" or "animal models" or animals or bovine or canine or cat or cats or cow or cows or dog or dogs or feline or hamster or hamsters or mice or monkey or monkeys or mouse or murine or ovine or pig or pigs or porcine or rabbit or rabbits or rat or rats or rodent* or sheep or veterinary).ti.

19. 17 not 18

20. limit 19 to English language

Study Selection

We included studies (controlled clinical trials and observational studies using control groups) that assessed the effects of plant-based cannabis preparations, whole-plant extracts (e.g., nabiximols), or FDA-approved synthesized pharmaceutically prepared cannabinoids (e.g., dronabinol, nabilone) in nonpregnant adults with PTSD. The full criteria for patient populations, interventions, comparators, outcomes, timing, settings, and study designs (PICOTS) are specified in Table A1. [28]

Using these prespecified inclusion/exclusion criteria (Table A1), all citations were reviewed for potential relevance using DistillerSR (Evidence Partners, Ottawa, Canada). Two reviewers independently screened the title and abstract of each citation, and inclusion by both of those reviewers progressed the citation to full-text review. At the full-text screening stage, 2 independent reviewers agreed on a final inclusion/exclusion decision for all articles; any disagreements were resolved through consensus or consultation with a third reviewer. Articles meeting eligibility criteria were included for data abstraction.

As the volume of literature retrieved in the searches is relatively small, we will screen all records manually without using the DistillerSR automated screening function; however, this or other automation techniques may be employed over time if the volume of retrieved citations increases substantially.

Table A1. PICOTS for Systematic Review of Cannabis for the Management of Symptoms of Posttraumatic Stress Disorder

Key Question	KQ1. What are the effects of cannabis on health outcomes and health care utilization for adults who have posttraumatic stress disorder (PTSD)? KQ2: Do the effects differ by patient subgroup, such as patient medical and mental health comorbidities?	
	INCLUDE	EXCLUDE
Population	Nonpregnant adults with PTSD. Studies with mixed-age (adult and < 18) population may be included.	Majority of the study participants are either of the following: • Younger than age 18 • Adults who are pregnant No other exclusions
Intervention/ Exposure	Cannabis preparations, including marijuana, hashish, tincture, hashish oil, infusion, and plant extract (including Epidiolex – an FDA-approved medication containing cannabidiol; and nabiximols [brand-name: Sativex] – a nonsynthetic pharmaceutical product with a standard composition and dosage) or FDA-approved synthesized, pharmaceutically prepared cannabinoids (Dronabinol [brand-names: Marinol and Syndros], Nabilone [brand-name: Cesamet]), alone or in combination with other intervention(s) All methods of administration (e.g., smoking, vaping, edibles)	Other synthesized cannabinoids (e.g., synthetic marijuana, spice, K2)
Comparator	Any other intervention or a nonexposed control group	Studies with no comparison group

Key Question	KQ1. What are the effects of cannabis on health outcomes and health care utilization for adults who have posttraumatic stress disorder (PTSD)? KQ2: Do the effects differ by patient subgroup, such as patient medical and mental health comorbidities?	
Outcomes *effectiveness outcomes and specific adverse effects of interest*	Validated PTSD clinical interviews and symptom inventories, such as: • Clinician Administered PTSD Scale (CAPS) • PSTD Checklist (PCL) • PTSD Symptom Scale (PSS) • Posttraumatic Diagnostic Scale (PDS), etc. • Validated measures of mental health symptoms commonly associated with PTSD (mood, depression, anxiety) • Validated measures of sleep quality (including nightmares, insomnia) • Validated measures of quality of life • Social functioning/disability/employment • Utilization of health services • Reduction in benzodiazepine use or dosage Harms: Several of the above outcomes may be either benefits or harms. Other adverse effects (AEs) of interest include: • Other substance use/substance use disorders • Psychosis • Study dropout due to AEs • For harms not listed here, if there is a 10% or greater difference between groups, then we will report	Laboratory, blood, or imaging findings All other outcomes
Timing	Short- and long-term outcomes Four-week minimum for efficacy outcomes	All outcomes of interest reported for duration of < 4 weeks
Setting	Any setting. All countries.	---
Study design	Controlled clinical trials (randomized or nonrandomized), and methodologically rigorous observational studies with a comparison group (case control/cohort studies) that adjust for important confounders	Case studies, case series, and cross-sectional studies

Abbreviations. FDA: Food and Drug Administration; PICOTS: population, interventions, comparators, outcomes, timing, setting, study design; PTSD: posttraumatic stress disorder

Data Abstraction

Data from published reports were abstracted into a customized database by 1 reviewer and confirmed by a second reviewer. From each study, we abstracted the following where available: study design, objectives, setting, population characteristics, subject inclusion and exclusion criteria, number of participants, duration of follow-up, the study and comparator interventions (including formulation, strength, etc.), important co-interventions, health outcomes, and harms.

Assessment of Risk of Bias of Individual Studies

Two reviewers independently assessed the risk of bias of each study using a tool developed by the Scottish Intercollegiate Guidelines Network (SIGN).[29,30] Disagreements were resolved through discussion. Each trial was given an overall summary assessment of low, moderate, or high risk of bias.

Data Synthesis

We summarized the primary literature by abstracting relevant data and qualitatively synthesizing the literature for each key question. We determined it was not feasible to complete a quantitative synthesis (i.e., meta-analysis) to estimate summary effects due to the low volume of relevant literature and conceptual homogeneity of the included studies.

Assessment of the Overall Quality of Evidence

We assigned select clinically- and patient-important outcomes a summary judgment for the overall quality of evidence based on the system developed by the Grading of Recommendations, Assessment, Development, and Evaluation Working Group (GRADE).[31] Two independent experienced researchers assigned ratings, with disagreements resolved by a third rater. The GRADE system defines the overall quality of a body of evidence for an outcome in the following manner:

- **High**: Raters are very confident that the estimate of the effect of the intervention on the outcome lies close to the true effect. Typical sets of studies are randomized controlled trials with few or no limitations, and the estimate of effect is likely stable.
- **Moderate**: Raters are moderately confident in the estimate of the effect of the intervention on the outcome. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is different. Typical sets of studies are randomized controlled trials with some limitations or well-performed nonrandomized studies with additional strengths that guard against potential bias and have large estimates of effects.
- **Low**: Raters have little confidence in the estimate of the effect of the intervention on the outcome. The true effect may be substantially different from the estimate of the effect. Typical sets of studies are randomized controlled trials with serious limitations or nonrandomized studies without special strengths.
- **Very low**: Raters have no confidence in the estimate of the effect of the intervention on the outcome. The true effect is likely to be substantially different from the estimate of effect. Typical sets of studies are nonrandomized studies with serious limitations or inconsistent results across studies.
- **Not applicable**: Researchers did not identify any eligible articles.

Surveillance in the Living Stage of the Systematic Review

When to Update

At least 1 new meaningful study should be identified to consider fully updating the systematic review. Nevertheless, one meaningful study alone might be insufficient to warrant a full update. Depending on the body of the literature and velocity of publication, an update might require multiple meaningful studies. The review team may consult the STEM TEP to help guide this process.

Whenever new evidence (meaningful studies, data, or other information) relevant to the review is identified, we will extract the data and assess the risk of bias (RoB), as appropriate. We will wait until the accumulating evidence changes 1 or more of the following components of the review before incorporating it and re-publishing the review:

- The findings of 1 or more primary outcomes, including the GRADE rating
- The credibility (e.g. GRADE rating) of 1 or more primary outcomes
- New settings, populations, interventions, comparisons, or outcomes studied

- New serious adverse events
- Other [author teams to specify]

In instances where a full update is not warranted (i.e., an updated search was conducted and no new studies were identified or the studies were insufficient to warrant a full update), we will state this on the relevant web pages and documents.

Repeated Meta-analysis

We will not apply type I or II error adjustment techniques for repeated meta-analysis, if conducted.

Subgroup Analysis and Assessing Heterogeneity

We will qualitatively summarize any reported subgroups. We will determine the feasibility of completing a quantitative synthesis of subgroups estimating summary effects depending on the volume of relevant literature, conceptual homogeneity of the studies, and completeness of results reported by included studies.

Methods for Further Updates

We will assess the review scope and methods annually, or more frequently if appropriate, in light of potential changes in the topic area or the evidence being included in the review (for example, additional comparisons, interventions, subgroups or outcomes, or new review methods available).

When to Stop

We will consider the necessity for the review to be living annually by assessing the ongoing relevance of the question to decision-makers and by determining whether uncertainty remains and whether further relevant research is likely.

Appendix B. Full Evidence Tables

Table B1. Findings from Eligible Studies

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
Randomized studies			
Bogenschutz et al., 2025[1] N = 29	600mg CBD for 6 weeks (200 mg capsules, two in the morning and one in the evening) vs. Placebo Baseline PCL-5 score, mean (SD): 45.7 (13.4)	PCL-5, Weeks 1-6 Marginal mean (95% CI) EG: 27.459 (21.415 to 33.502) CG: 25.899 (18.935 to 32.863) Estimated difference (95% CI); 1.56 (-7.66 to 10.78); *d* = .13	Depression, BDI-II, Weeks 1-6 Marginal mean (95% CI) EG: 17.773 (14.441 to 21.105) CG: 20.443 (16.785 to 24.102) Estimated difference (95% CI); -2.67 (-7.62 to 2.28); *Cohen's d* = -.42 Anxiety, BAI, Weeks 1-6 Marginal mean (95% CI) EG: 11.080 (7.482 to 14.676) CG: 13.279 (9.275 to 17.284) Estimated difference (95% CI); -2.20 (-7.58 to 3.18); *Cohen's d* = -.33

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
Bonn-Miller et al., 2021[3] N = 80	*Stage 1* (3 wks) – 3 groups smoked cannabis (High THC, High CBD, THC+CBD) and 1 PBO 2-week washout *Stage 2* (3 wks) – 3 groups smoked cannabis (High THC, High CBD, THC+CBD) Baseline PTSD severity (PCL-5) mean (SD): 43.7 (15.0)	<u>CAPS-5 total severity mean change (SD)</u> *Stage 1* High THC: -15.2 (11.03); *P* < .05 High CBD: -8.4 (10.09); *P* < .05 THC + CBD: -8.5 (9.88); *P* < .05 Placebo: -13.1 (12.10); *P* < .05 between groups analysis of differences: F(3, 73) = 1.85, *P* = .15 *Stage 2* High THC: -3.3 (8.22); *P* ≥ .05 High CBD: -0.48 (9.07); *P* ≥ .05 THC + CBD: -11.8 (12.97); *P* < .05 No placebo between groups analysis of differences: F(2, 64) = 6.92, *P* = .002 <u>PCL-5 mean change (SD)</u> *Stage 1* High THC: -23.5 (16.5); *P* < .05 High CBD: -12.1 (16.2); *P* < .05 THC + CBD: -16.4 (9.1); *P* < .05 Placebo: -14.6 (15.6); *P* < .05 between groups analysis of differences: F(3, 71) = 2.10, *P* = .11 *Stage 2* High THC: -9.1 (11.0); *P* < .05 High CBD: -5.7 (9.3); *P* ≥ .05 THC + CBD: -16.4 (16.0); *P* < .05 between groups analysis of differences: F(2, 63) = 4.06, *P* = .02	<u>General depression, IDAS mean (SD)</u> *Stage 1* High THC: -16.1 (12.6); *P* < .05 High CBD: -11.4 (11.7); *P* < .05 THC + CBD: 8 -13.4 (9.1); *P* < .05 Placebo: -8.3 (11.2); *P* < .05 between groups analysis of differences: F(3, 72) = 1.67, *P* = .18 *Stage 2* High THC: -9.0 (11.1); *P* < .05 High CBD: -4.4 (12.4); *P* ≥ .05 THC + CBD: -13.4 (10.9); *P* < .05 between groups analysis of differences: F(2, 63) = 3.08, *P* = .05 <u>Social anxiety, IDAS mean (SD)</u> *Stage 1* High THC: -3.7 (4.2); *P* < .05 High CBD: -2.7 (2.7); *P* < .05 THC + CBD: -2.2 (2.0); *P* ≥ .05 Placebo: -2.4 (4.3); *P* ≥ .05 between groups analysis of differences: F(3, 72) = .67, *P* = .58 *Stage 2* High THC: -1.8 (3.1) High CBD: -0.04 (2.7) THC + CBD: -2.8 (3.9) between groups analysis of differences: F(2, 63) = 3.76, *P* = .03

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
			<u>Insomnia, ISI mean (SD)</u> *Stage 1* High THC: -8.8 (5.20); *P* < .05 High CBD: -5.9 (6.50); *P* < .05 THC + CBD: -6.6 (5.18); *P* < .05 Placebo: -6.1 (5.70); *P* < .05 between groups analysis of differences: F(3, 71) = 1.00, *P* = .40 *Stage 2* High THC: -4.2 (5.45); *P* < .05 High CBD: -3.9 (5.68); *P* ≥ .05 THC + CBD: -5.5 (5.66); *P* < .05 between groups analysis of differences: F(2, 63) = .46, *P* = .63 <u>Psychosocial functioning, IPF mean (SD)</u> *Stage 1* High THC: 1.2 (11.9); *P* ≥ .05 High CBD: -1.2 (5.5); *P* ≥ .05 THC + CBD: 4.1 (8.5); *P* ≥ .05 Placebo: -0.2 (6.7); *P* ≥ .05 between groups analysis of differences: F(3, 72) = 1.34, *P* = .27 *Stage 2* High THC: 0.59 (7.0); *P* ≥ .05 High CBD: 0.28 (4.9); *P* ≥ .05 THC + CBD: 1.2 (8.2); *P* ≥ .05 between groups analysis of differences: F(2, 63) = .09, *P* = .91

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
			<u>Harms with > 10% difference in rate of occurrence between groups</u> *Stage 1* High THC vs. High CBD vs. THC+CBD vs. PBO (each group N = 20) Dry mouth: 15% vs. 5% vs. 0% vs. 0% Nausea: 10% vs. 0% vs. 30% vs. 5% Upper respiratory tract infection: 10% vs. 5% vs. 5% vs. 15% Back pain: 10% vs. 0% vs. 5% vs. 0% Dizziness: 10% vs. 0% vs. 15% vs. 0% Headache: 15% vs. 5% vs. 20% vs. 25% Somnolence: 15% vs. 0% vs. 0% vs. 0% Irritability: 10% vs. 5% vs. 5% vs. 0% Paranoia: 5% vs. 0% vs. 25% vs. 0% Throat irritation: 5% vs. 20% vs. 15% vs. 30% *Stage 2* High THC (N=29) vs. High CBD (N = 27) vs. THC+CBD (N = 18) Nausea: 10.3% vs. 0% vs. 13.2% Heat exhaustion: 0% vs. 0% vs. 11.1% Irritability: 3.4% vs. 3.7% vs. 16.7% Cough: 6.9% vs. 7.4% vs. 25.9%

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
Jetly et al., 2015[2] N = 10	Group 1 — Period 1 nabilone (NAB) up to 3 mg; Period 2 placebo (PBO) Group 2 — Period 1 placebo (PBO); Period 2 nabilone (NAB) up to 3 mg 7 weeks each period with 2-week washout between Baseline PTSD severity (Global Impression of Severity of PTSD): 3.3 (0.9)	Nabilone vs. placebo Mean change (SD) PTSD-related nightmares: CAPS recurring and distressing dream items (frequency + intensity) -3.6 (2.4) vs. -1.0 (2.1); *P* = .03[a] Frequency item −1.9 (1.3) vs. −0.4 (1.4); *P* = .05[a] Intensity item −1.7 (1.3) vs. −0.6 (1.1); *P* = .06[a]	Nabilone vs. placebo Mean (SD) Functional status: Impression of change (CGI-C)[b] 1.9 (1.1) vs. 3.2 (1.2); *P* = .05[a] Sleep: Difficulty falling and staying asleep (CAPS items) No difference (scores NR) Sleep quantity, hours (sleep diary) 7.6 (1.9) vs. 7.4 (2.0); *P* = .97[a]

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
Nonrandomized studies			
Bonn-Miller et al., 2020[7] N = 150	Self-reported cannabis use 1+ times/ week vs. no use in preceding 6 months Baseline PTSD severity (CAPS-5 total mean score [SD]): 36.88 (8.52) vs. 36.33 (8.46); *P* = .69	Exposure group vs. control Group by time interaction CAPS-5 PTSD symptom severity -0.32 (95% CI, -0.59 to -0.05)	Exposure group vs. control Group by time interaction Functional status: Psychosocial functioning (IPF total) 0 (95% CI, -0.02 to 0.02) Sleep: Sleep quality (PSQI total) -0.01 (95% CI, -0.12 to 0.10) Insomnia (ISI total) -0.12 (95% CI, -0.27 to 0.03) Sleep-onset latency, min 0.30 (95% CI, -0.68 to 1.28) Sleep efficiency, % 0 (95% CI, -0.26 to 0.27) Wake after sleep onset, min -0.38 (95% CI, -1.07 to 0.31) Number of awakenings 0.73 (95% CI, 0.13 to 1.33)

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
De Aquino et al., 2020[4] N = 1,413	Self-reported history of ≥ 7 days of concurrent non-medical opioid and cannabis use over the 30 preceding days (n = 428) vs. ≥ 7 days of nonmedical opioid use, but no cannabis use over the 30 preceding days (n = 985). Concomitant treatment: all participants were receiving intensive PTSD treatment. Baseline PTSD Symptom Severity (Combined MISS SF and VA's NEPEC PTSD assessment tool;[32] mean [SD]): Exposure group 3.7 (0.4) vs. control group 3.6 (0.4)	Exposure group vs. control Mean (SD) Change in PTSD symptom scores at 4 months: Total PTSD symptom score −0.36 (0.56) vs. −0.26 (0.52); *P* = .03 Numbness −0.23 (0.58) vs. −0.14 (0.59); *P* = .03 Arousal −0.40 (0.6) vs. -0.34 (0.6); *P* = .15 Reexperiencing −0.34 (0.78) vs. −0.26 (0.77); *P* = .07 Avoidance −0.26 (1.1) vs. −0.25 (1.1); *P* = .83 Suicidal thoughts −0.48 (1.1) vs. −0.38 (1.0); *P* = .04 Irritability −0.36 (1.1) vs. −0.37 (1.1); *P* = .90 Violent behavior −0.99 (1.6) vs. −1.02 (1.5); *P* = .75	Exposure group vs. control Mean (SD) Status 4 months after the program: Change in ASI score (alcohol) −0.20 (0.38) v. −0.20 (0.30); *P* = .99 Change in ASI score (drug) −0.23 (0.23) vs −0.24 (0.17); *P* = .91 Index of substance use days (0–150) 11.3 (22.1) vs. 7.9 (17.5); *P* = .07 Number of different substances used 0.79 (1.3) vs. 0.58 (0.9); *P* = .08 Number of days of ≥ 3 drinks (past 30 days) 2.18 (6.97) vs. 2.0 (5.2); *P* = .69 Number of days of nonmedical opioid use (past 30 days) 3.13 (4.6) vs. 3.62 (5.7); *P* = .48 Number of days of nonmedical sedative use (past 30 days) 0.76 (10.2) vs. 1.42 (9.21); *P* = .11

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
			Number of days of cocaine use (past 30 days) 0.71 (4.62) vs. 4.88 (0.62); *P* = .73 Number of days of nonmedical amphetamine Use (past 30 days) 0.09 (2.1) vs. 0.14 (1.3); *P* = .70 Number of days of nonmedical cannabis use (past 30 days) 1.63 (8.3) vs. 1.49 (3.2); *P* = .88
Petersen et al., 2021[8] N = 340	Any use: diagnosis of cannabis abuse or dependence, THC-positive UDS, documentation of cannabis use in progress notes, or non-VA medication list reporting medical cannabis prescription while admitted to the program vs. no cannabis use (none of the above documentation of use) Concomitant treatment: Intensive outpatient PTSD treatment including evidence-based therapy (CBT, CBT & MET, PE, supportive psychotherapy, or unspecified EBT) Baseline PTSD severity (PCL-5), mean (SD): 64.0 (9.8) vs. 61.6 (11.2), *P* = .07	Change in PCL, mean (SD): 5.7 (14.7) vs. 6.0 (14.0); *P* = .79 Treatment success[c]: 51.9% vs. 51.4%; *P* = .94 Cannabis use effect on odds of treatment success: aOR, 1.4 (95% CI, 0.81 to 2.5) Controlled for: antidepressant use and other SUDs	NR

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
Ruglass et al., 2017[6] N = 136	Self-reported cannabis use within 7 days of baseline assessment for the clinical trial (n = 32) vs. no cannabis use within 7 days of baseline (n = 104) Concomitant treatment: CBT, or CBT + Sertraline, or CBT + Placebo - aimed at treating both PTSD and SUD Baseline PTSD severity: NR	Baseline days of cannabis use were not a significant predictor of PTSD symptom severity at the end of treatment (*P* = .30). Higher weekly cannabis use was associated with greater weekly PTSD symptom severity early in treatment but lower weekly PTSD symptom severity later in treatment.	Baseline days of cannabis use were not a significant predictor of substance use at the end of treatment (*P* = .84).
Wilkinson et al., 2015[5] N = 2,276	Self-reported cannabis use during 4-month follow-up: Never-users: 850 Stoppers: 299[d] Continuing users: 296[e] Starters: 831[f] Concomitant treatment: all participants were receiving intensive PTSD treatment. Baseline PTSD Symptom Severity (MISS SF; mean [SD]): Stoppers: 39.87 (5.40) Continuing users: 39.73 (5.59) Starters: 40.20 (5.72) Never users: 39.63 (6.00) *P* = .23	MISS (SF) Scores, LS Mean (SE)[g]: Stoppers: 36.64 (0.39) Continuing users: 38.92 (0.38) Starters: 39.67 (0.23) Never users: 37.71 (0.23) *P* < .0001 Effect of starting cannabis use (compared to never using) on PTSD symptoms[h] SMD: +0.34 Effect of stopping SMD: −0.18 Multivariate regression results Change in days of marijuana used and change in[h]: PTSD symptoms (β = 0.17, t = 4.08, *P* < .0001)	Violent behavior 4-item questionnaire from the National Vietnam Veterans Readjustment Study[22] (LS mean [SE]):[g] Stoppers: 0.76 (0.07) Continuing users: 0.93 (0.07) Starters: 1.25 (0.04) Never users: 0.87 (0.04) *P* < .0001 Alcohol abuse ASI Alcohol Index (LS mean [SE])[g]: Stoppers: 0.08 (0.01) Continuing users: 0.13 (0.01) Starters: 0.23 (0.01) Never users: 0.10 (0.01) Drug abuse ASI Index (LS mean [SE])[g]: Stoppers: 0.03 (0.01) Continuing users: 0.13 (0.01) Starters: 0.13 (0.003) Never users: 0.04 (0.003) *P* < .0001

Study N	Cannabis Use and Comparators Baseline PTSD symptom severity	Primary Findings	Other Findings
			<u>Employment status</u> ASI Index (LS mean [SE])[g]: Stoppers: 0.58 (0.01) Continuing users: 0.59 (0.01) Starters: 0.58 (0.01) Never users: 0.58 (0.01) *P* = .58 <u>Multivariate regression results</u> Change in days of marijuana used and change in: severity of violent behavior (β = 0.10, t = 2.79, *P* = .005); ASI alcohol index (β = 0.24, t = 5.60, *P* < 0.0001); ASI drug abuse index (β = 0.65, t = 21.62, *P* < .0001).[h]

[a] P < .01 considered significant; [b] 1 = very much improved and 7 = very much worse; [c] Success means ≥ 5-point decrease in PCL; [d] Used cannabis before but not after admission; [e] Used cannabis at admission and continued using; [f] Did not use cannabis before admission but started afterward; [g] Co-varying for marital status; age; race; history of incarceration; waiting list status; psychosis; chronic medical problems; war zone service; length of stay; expulsion from treatment; and baseline measures of violence, PTSD, drug and alcohol abuse, and employment; [h] Adjusted for: age, race, marital status, War Zone Service, drug and alcohol abuse, chronic medical problems; employment status at admission, violence at admission, incarceration history, willing to attend reunion, program length of stay, program expulsion, and waiting list status.
Abbreviations. ASI: Addiction Severity Index, CBT: cognitive behavioral therapy, CGI-C: Clinical Global Impression of Change, EBP: evidence-based psychotherapy, IDAS: Inventory of Depression and Anxiety Symptoms, IPF: Inventory of Psychosocial Functioning, ISI: Insomnia Severity Index, LS: least squares, MET: motivational enhancement therapy, MISS: Mississippi Scale for PTSD, NAB: nabilone, NEPEC: Northeast Program Evaluation Center, PBO: placebo, PCL: PTSD checklist, PE: prolonged exposure therapy, PTSD: posttraumatic stress disorder, PSQI: Pittsburgh Sleep Quality Index, SD: standard deviation, SE: standard error, SF: short form, SMD: standard mean difference, SUD: substance use disorder, VA: Veterans Affairs.

Table B2. Risk of Bias for Randomized Controlled Trials

Study	1	2	3	4	5	6	7	8	9	10	11	12	Overall RoB
Bogenschutz et al., 2025[1]	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	NA	No	Yes	High
Bonn-Miller et al., 2021[3]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Can't say	No	Yes	Low
Jetly et al., 2015[2]	Yes	Yes	Can't say	Yes	Can't say	Yes	Yes	Yes	Yes	NA	No	Yes	High

Abbreviations. NA: not applicable; ROB: risk of bias.

SIGN Methodology Checklist 2: Randomised Controlled Trials[29]

1. *The study addresses an appropriate and clearly focused question.*
2. *The assignment of subjects to treatment groups is randomised.*
3. *An adequate concealment method is used.*
4. *Subjects and investigators are kept 'blind' about treatment allocation.*
5. *The treatment and control groups are similar at the start of the trial.*
6. *The only difference between groups is the treatment under investigation.*
7. *All relevant outcomes are measured in a standard, valid and reliable way.*
8. *What percentage of the individuals or clusters recruited into each treatment arm of the study dropped out / crossed over before the study was completed? [Was there balanced retention?]*
9. *All the subjects are analysed in the groups to which they were randomly allocated (intention to treat (ITT) compared with per protocol (PP) analysis).*
10. *Where the study is carried out at more than one site, results are comparable for all sites.*
11. *Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, are you certain that the overall effect is due to the study intervention?*
12. *Are the results of this study directly applicable to the patient group targeted by this guideline/report?*

Table B3a. Risk of Bias for Cohort Studies

Citation	1	2	3	4	5	6	7	8	9
Bonn-Miller et al., 2020[7]	Yes	No	Yes	NA	33%	No	No	Yes	No
De Aquino et al., 2020[4]	Yes	No	NA	NA	Can't say	Can't say	No	Yes	NA
Petersen et al., 2021[8]	Yes	No	NA	NA	Can't say	Can't say	No	Yes	NA
Ruglass et al., 2017[6]	Yes	No	Yes	NA	28.5%	No	No	Yes	NA
Wilkinson et al., 2015[5]	Yes	No	NA	NA	Can't say	Can't say	No	Yes	NA

Abbreviations. NA: not applicable

SIGN Methodology Checklist 3: Cohort Studies[30]

1. *The study addresses an appropriate and clearly focused question.*
2. *The two groups being studied are selected from source populations that are comparable in all respects other than the factor under investigation.*
3. *The study indicates how many of the people asked to take part did so, in each of the groups being studied.*
4. *The likelihood that some eligible subjects might have the outcome at the time of enrolment is assessed and taken into account in the analysis.*
5. *What percentage of individuals or clusters recruited into each arm of the study dropped out before the study was completed?*
6. *Is the dropout percentage reported acceptable?*
7. *Comparison is made between full participants and those lost to follow up, by exposure status.*
8. *The outcomes are clearly defined.*
9. *The assessment of outcome is made blind to exposure status. If the study is retrospective this may not be applicable.*

Table B3b. Risk of Bias for Cohort Studies Continued

Citation	10	11	12	13	14	15	16	17	Overall RoB
Bonn-Miller et al., 2020[7]	No	Yes	Yes	Yes	Yes	Yes	No	Yes	High
De Aquino et al., 2020[4]	NA	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Petersen et al., 2021[8]	NA	No	Yes	Can't say	No	Yes	No	Yes	High
Ruglass et al., 2017[6]	NA	No	Yes	Yes	No	Yes	No	No	High
Wilkinson et al., 2015[5]	NA	Yes	No	Yes	Yes	Yes	Yes	Yes	Moderate

Abbreviations. NA: not applicable; ROB: risk of bias.

Continued from Table B3a:

10. *Where blinding was not possible, there is some recognition that knowledge of exposure status could have influenced the assessment of outcome.*
11. *The method of assessment of exposure is reliable.*
12. *Evidence from other sources is used to demonstrate that the method of outcome assessment is valid and reliable.*
13. *Exposure level or prognostic factor is assessed more than once.*
14. *The main potential confounders are identified and taken into account in the design and analysis.*
15. *Have confidence intervals been provided?*
16. *Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, do you think there is clear evidence of an association between exposure and outcome?*
17. *Are the results of this study directly applicable to the patient group targeted in this guideline?*

Appendix C. Bibliography of Included Studies

Bogenschutz MP, Blessing E, Dgheim D, Cho D, Zhang J, Laska EM, et al. Effects of cannabidiol in alcohol use disorder patients with and without co-occurring post-traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof-of-concept trials. Randomized Controlled Trial. *Alcohol (Hanover)*. Jan 2026;50(1):e70212. doi:https://dx.doi.org/10.1111/acer.70212

Bonn-Miller MO, Brunstetter M, Simonian A, Loflin MJ, Vandrey R, Babson KA, et al. The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder. *Cannabis Cannabinoid Res*. 2020. doi: 10.1089/can.2020.0056.

Bonn-Miller MO, Sisley S, Riggs P, Yazar-Klosinski B, Wang JB, Loflin MJE, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. *PLoS ONE*. 2021;16(3):e0246990. doi: https://dx.doi.org/10.1371/journal.pone.0246990.

De Aquino JP, Sofuoglu M, Stefanovics EA, Rosenheck RA. Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. *Am J Drug Alcohol Abuse*. 2020:1-11. Epub 2020/10/10. doi: 10.1080/00952990.2020.1818248.

Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology*. 2015;51:585-588. Epub April 12, 2014. doi: 10.1016/j.psyneuen.2014.11.002.

Petersen M, Koller K, Straley C, Reed E. Effect of cannabis use on PTSD treatment outcomes in veterans. *Ment Health Clin*. 2021;11(4):238-42. doi: https://dx.doi.org/10.9740/mhc.2021.07.238.

Ruglass LM, Shevorykin A, Radoncic V, Smith K, Smith P, Galatzer-Levy I, et al. Impact of cannabis use on treatment outcomes among adults receiving cognitive-behavioral treatment for PTSD and substance use disorders. *J Clin Med*. 2017;6(2):07. doi: 10.3390/jcm6020014.

Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. *J Clin Psychiatry*. 2015;76(9):1174-80. Epub 2015/10/13. doi: 10.4088/JCP.14m09475.